News: CME Group (NASDAQ:CME) currently holds a “Moderate Buy” consensus rating from eighteen analysts covering the firm. Two analysts rate the stock as a sell, six as a hold, eight as a buy, and two as a strong buy. The average twelve-month price target is $307.5882. Recent analyst activity includes price target increases from TD Cowen ($328.00), Goldman Sachs ($275.00), and Rothschild & Co Redburn ($347.00). CME Group reported Q1 2024 average daily volume (ADV) of a record 11.4M contracts, up 30% year-over-year. The company is expanding its crypto offerings with the launch of Avalanche (AVAX) and Sui (SUI) futures on May 4th. CME Group also increased its quarterly dividend to $1.30 per share. Institutional investors, including Vanguard Group, State Street Corp, Norges Bank, Bank of New York Mellon, and Ameriprise Financial, have increased their positions in the company. CME Group’s Q1 earnings beat estimates at $2.77 EPS.
AI Analysis: The positive analyst ratings, coupled with record trading volumes, crypto expansion, and increased institutional investment, suggest a bullish outlook for CME Group. The dividend increase further enhances its appeal to investors.
